will not by letting go do that, but it didn't stop all impulse desktop google impulse, but they would continue to import gas. they're continuing to import other critical minutes. so what is this new delhi and that's not important. the government does not import. it's are oil entities that input all entities out in the public sector and in the private sector, the new non cooperation, which is the 7th largest company in the world and downstream. they are one of them, made an importer as what they do and what everybody does. is to florida, send us at the point of importation, let's say please let us know how much of this this we need so much one to be of this group deliberate at this point. if it is heavy girl, part of the, okay, it was either maybe the other thoughts of importation. there's another thing that i shouldn't company quotes unless the price good is that i shouldn't company cause a high price, the environment, the present list price. so they're also audited,

so there is no decision when the in february 2022. when did i show you okay, and military conflict, the place at that stage i would import from the shuttle is 0.2 percent. today then 30 percent is under decline. it gets a massive into, oh, i live in america 33 up before comes down. but you know, even be in port 5000000 bottles or the consumer 5000000 barrels on a particular day. you might have it all cause a lot of restaurant. maybe that then so the maybe that it depends on price and availability in this situation is that important crude oil are the biggest item in that in port bhaskar. and equally the export of petroleum products is the biggest item in unexplored basket. so we will import from whatever we category, like sports or whatever because now there are a lot of new plans coming on the block. we're not part of a big plus

a dyna as new. i think of city nom is new, maybe as new, brazil as lot that are members of a big range and sharma also attended the farm and go and send us a report from the events beyond the indian western states. the best lines, the analogy, sex though from all across the world have gathered their deliveries. they want opportunities at the time when the was raffles with an analogy crisis bureau to the 2nd edition of india, n o g week, the indian, minnesota sodium and natural gas as a meeting holding by lots and just like before, he does done it again. it's yeah, the one the does on the one of the houses of exhibit those thousands of delegates that have gone. yeah, but them a 6 for when he is including russia, canada, u. s. u k. so that's dialogue on the india's need to ship once again and this is

about an o g. but of course, the main focus mean agenda for india. read the notes is 0 for the coming years. and in terms of for the operations companies, there's a pause or in india, this is one of them was to look at as a pop. now i do stay with us up next. the cost of everything by the, the, the know diagnosis strikes fear into the hearts of patients more than the dreaded c word cancer. it is a war we all fear and yet every day, more of us are forced to face it. unfortunately, it is becoming more more common as a world health organization has revealed that it has overtaken heart disease as the

biggest killer globally, the growth and the incidence of cancer parallel as the industrialization and chemical as agent of the world. the more developed the country is, the more cancer, there is the higher per capita income, the higher incidence of cancer. i'm christy, and you're watching the cost of everything we're today. we're going to be faced with the cost of cancer. cancer is the 2nd leading cause of death in the us. but luckily, today, many kinds of cancer can be prevented or caught early. leading risk factors for preventable cancers, our smoking, getting too much uv radiation being overweight and drinking too much alcohol. at this point, one and every 3 people, you know, will have cancer in their lifetime, which is a horrifying statistic. but has cancer,

survival rates go up. so the price tags of life saving treatments, monthly drug costs may reach a $100000.00, causing money to struggle with the high costs, even worse. others are completely priced out of even the hope for cure low income families, that americans who are uninsured or under insured face medical bills, more than 4 times their annual salaries, and simply cannot afford the rise and call cost of cancer treatments. cancer patients are 2 and a half times more likely to declare bankruptcy and 71 percent are more likely to experience a severe adverse financial event then healthy people. now, in the us alone, over 1900000 new cancer cases were diagnosed in 2023. the average total cost of cancer treatments run in the a $150000.00 range, but it doesn't paint an accurate picture. total out of pocket costs depend on

a number of factors including insurance coverage, the types of cancer and treatment, the frequency of treatment, and the costs related to the cancer center. key will therapy is one of the most common cancer treatments. and depending on the drugs and the type of cancer at the average monthly cost of chemo can range from a $1000.00 to $12000.00. if a patient requires 4 rounds of chemo, then that would cost some up to $48000.00 total. we just beyond the average annual income, all their costs associated with cancer include hiring caregivers or a home health aide. transportation lost wages by specialty items such as certain types of food wigs or fertility treatments that can all add up of 4 of the 5 most expensive cancer drugs on the markets are types of amino therapies. these drugs cost as much per month, then what the average american makes and a year, which is $52800.00. but ironically, despite the high price tag,

the drugs don't work for most patients. a studies showed only 13 percent of patients actually benefit from these types of treatments. and now today we're joined by doctor has shown posing oncologist at christmas saint michael on ecology clinic. now dr. which types of cancers are most prevalent on a global scale, and how has this changed over the years? so cancer varies between different populations and every type is rare in some part of the world. many specific causes are now known um, but a large proportion of global variation for common can't just remain on remains unexplained. considering both sexes, either female breast, male, prostate or several cancer, as most commonly diagnosed cancer over the in over 70 percent of the countries. um the, the number of cases had been increasing, but the number of new cases in deaths had been decreasing over the past 20 years, which is pretty example right. as far as the most common cancer is, it depends on which areas we're talking about. the most common problem in kansas

around the gold is breast cancer. the, the most common cause of death of cancer around the world as lung cancer is now. and if we're talking about particular regions, mostly north america, uh, north america, uh, a western europe. uh, mostly its a female with breast cancer and most of the most common causes lung cancer. so certain populations in west africa and said that south africa, the most common is cervical cancer. and those are the reasons for that as far as um, certain places in asia and mongolia, most common is liver cancers. and south of japan is stomach cancer, gastric cancer. so all depends. but yeah, that's those are the most common that we see roles a lot to and gladly we are, you know, thankfully, there has been decrease in cases over the past 1015 years. are there a particular reasons or countries experience a higher incidence of certain cancers? yeah, pretty much uh, in terms of uh, certain regions uh, like i said,

most highly industrialized countries mostly is preston, uh, breast cancer as well as by mail, prostate cancer and lung cancer. the reason is because there's better screenings in those countries. um as far as uh, those other regions i mentioned before so south africa and western western africa the higher incidence. and that's from several cancer because there is a lack of screening a circle cancer. there's a very simple test that we do call the pap smear, which is not developed in those countries. hopefully there be proceeding along as far as mongolia that i mentioned before. there's a high high instance of liver cancer over any other cancer. and the reason is the high rates of hepatitis b and c in the re, uh, and alcohol alcohol consumption, which is a, has a high propensity for developing liver cancer. as far as, uh, salt depends um, through there are that most common is gastric cancer. and the reason for that is the smoke meets that they use and the high incidence of age priority, which you look, he would go back to by lori, which is

a bacteria infection which is known to cause stomach cancer. what cultural or environmental factors might contribute to these regional variances? well, the cultural is pretty much, uh, maintaining a healthy lifestyle. and i think some of the cultures that we see around the world, even including a united states in western europe, the, the, the culture that we see is, you know, less less of a healthy lifestyle, more propensity to being towards uh, having uh hi. hi saturated set. aside the diets as well as increase to their store, increased amounts of smoking in those parts of the world. but those are the most common causes of a of incidence of a lot of those cancer. and like i said, mentioned before, 70 percent of them are unexplained, but yeah, now those are the culture lifestyles. and just sometimes having basic, you know, mentoring needs is, can lead to cancer's. unfortunately in those lower income uh,

lower income countries. they don't have access to health care, they don't have access to screen programs, even some certain parts united states. there's no access to screening either a significant differences in cash or outcomes between high income and low income countries. yeah, overall, although the overall into this case is lower in lower income countries compared with high income countries, the total cancer related mortality is significantly higher and lower income countries, especially for people younger than age of 65. and the greater economic impact as a result is premature mortality and loss of yours productivity. it's especially a problem that for these low income countries, i think in 2015, 78 percent of all global data triple to non communicable diseases including cancer occurred in lower income countries with nearly 50 percent of debts in lower income countries. considered to be premature. so pretty much we're seeing them in the younger populations. um, just because of the lack of screening and when they catch these certain types of

cancers and these lower income countries that are always advance and stage disease locally advanced disease where the, the mortality is higher, especially as opposed to patients that people, patients are people in hiring countries have access to screening. they have treated early the a, catch that early disease and they survive longer because they're either treated with surgery, radiation, or chemotherapy. so although the incidence is higher and higher income countries because of the screening, the mortality is higher and lower income and how, how the technological advancements such as precision medicine and amino therapy impact of the cost and advocacy of cancer treatments globally. and are there disparities and the adoption of these technologies across different countries? well, with advent of amino therapy, which came about and well, certain drugs came and prior to 2012 most come immunotherapy tab came in 2012. there had been, uh for the past 4 years, the precision medicine which is based on something called next generation

sequencing or molecular testing in which we could pinpoint and have a predictive, precise, accurate attack form a attack towards these cancer. so basically what these look good testing is precision testing models on or these testing performs is basically gene panel and. ringback you take, i've done a fine actionable mutations in which the oncologist can predict a good could provide, provide a certain to care a certain type of drug that tax the certain attacks the cancer itself. so for since the advent of time, oncology care is basically using conventional chemotherapy which is kind of like a quote unquote shopping approach in which it destroys all cells. it just attacks the dna and unfortunately there is severe side effects associated with. ringback the advent of target, the therapy with for example targeting kinase inhibitor is basically attacking a certain types of cancer cells or immunotherapy which makes them in the system.

hyper vigilant or on mass the tumor. it allows for better precision, guided uh, therapy for cancer and has allowed for higher response rates, longer duration of responses, disease, free survival, and more importantly, overall survival which has impacted cancer care in the past 20 years given her and trends what the for see as a future challenges and opportunities in addressing the global impact of cancer. busy and vaccines are sometimes a little disappointed in cancer diagnosed to a screen equipment in surgical facilities that may be non existent. often cancer patients in low income countries are not diagnosed until disease beds making from treatment less effective and more costly. um, so um those are that mostly the future challenges is how much one, how much gum regulation prevents for the access to health care and to pretty much the population access to screening and diagnostic testing and allowing the long

term treatment for early stage disease. thank you. so much dr. heavy, but please stick around. the doctor has shown has a must stay with us right after the break and when we come back, not only the patients have to deal with the burden of the disease, but also the burden associated with cancer care will have more after the break, the

the even one diagnosed early and attacked with the latest treatments. cancer still has the power to kill according to the world health organization, the 3 can so it that killed the most people worldwide in 2020 and were lung cancer . at 1800000, that's colorado counts or 916000 deaths and liver cancer at 830000 deaths. the prostate cancer and breast cancer on the other hand are among the most common and prevalent types of cancer. now a cancer diagnosis can affect life in many ways for both the people with cancer and for their families. in addition to the many physical and emotional challenges, many people worry about how they will pay for the treatment or what will happen if they aren't able to work or need to make a change and how they work. in 2019,

the national patient economic burden associated with cancer care was estimated to be $21000000000.00. this estimate includes out of pocket cost, at $16200000000.00 and patient time cost of $4900000000.00. without insurance. the national cancer institute found that the average cost of medical care and drugs to be over $42000.00 in a year after a cancer diagnosis. they tend to have poor access to care poor cancer outcomes and experienced a greater amount of financial hardship. they also tend to be diagnosed with cancer at a late stage when the disease is also harder to treat. of the global oncology market was valued at over $200000000000.20. and this is expected to reach over $400000000000.00 by 2032. and unfortunately therapies now routinely cost

more than $100000.00 per year. and many of these therapies are often mis prescribed . a study found that physicians who consistently put pharmaceutical money in their bank accounts or more likely to prescribe that companies drugs. meanwhile, on colleges are hesitant to prescribe generics because such prescriptions cost them money, oncologists receive a 6 percent markup, meaning when they infuse a patient with a $10000.00 monthly course, a chemo, their practice yields an extra $600.00. if they prescribe generic, they would be out most of that extra money. so unfortunately, while you're forced to trust that your physician has your best interest at heart, that may not always be the case. so for this and more, let's bring in again, doctor has sean housing oncologist at christmas, same michael oncology clinic now what factors contributed to the high cost associated with the different types of cancer treatments? so the factors, um, basically,

and i'm pretty much going to be talking about most of the united states, i guess because i, i'm well versed in that. but the health care delivery systems are 3rd party pairs private or government, which covers the cost of cancer treatment in ensure public has a presume and possibly go right across all proved drugs, which is a debate with himself. the starting price of cancer drugs have at least 3 major problems. first, absolute crossing cost to society will become increasingly on affordable um to with some of the cancer drugs that are not the approved basically through regulations that leads to increased costs, which is out of pocket for the patient. and, and um, and basically a new drugs are unpredictable and geographically viable as a result, charge, patients in need to be meaningful, increase to keep up with the costs of care. and basically off label use may use expenditures and drugs that offer little to know, express advocacy, which we don't know about the so basically other factors are basically depends

system which leads to a monopoly. this is doing parts of biological conducting and cancer. basically, certain drugs attack certain parts of the dna, certain companies can have a plan on it and that could lead to less innovation. and just having one company control that drug in particular. and this is due basically to regulation high cost of developing the drugs. so basically in order to meet certain regulations, the drug companies have to spend a certain, uh, certain amount of money to go from bench research to actual clinical trials which leads to a problem with that itself. so those are the multiple, multiple factors that we see that are impacting the impacting kendra care and access the cancer care. can you break down the typical expenses involved in cancer treatment, including medication surgeries and other interventions? well, well, good talking to in terms of cancer drugs, basically in early 2000 and ten's, you know,

cancer care for certain medications to undergo chemo therapy was about $1500.00, you know, in terms of medication out of pocket for the patient. now in 2020 are, you know, from the, from the studies that we have from 2020, nothing after 2020 that are definite, but the average cost for a person to undergo keyma therapy in terms of medications. doctors, appointments of no transportation or social economic factors basically went from $1500.00 to $5000.00. now, as far as chemo therapy goes for a certain drug, one type of amino therapy, 3 doses are equivalent to $12000.00, which is pretty, pretty high. for surgery that would be almost as the cost of of surgery or even radiation therapy itself. these costs of these newer drugs which are amazing in terms of breakthrough technology and increasing lights are in light survival in

terms of cancer patients. unfortunately, these are highly expensive drugs and one because of like i mentioned before, monopoly government regulations, which increased costs from the pharmaceutical companies and the lack of uh, coverage from insure insurances. so hopefully the answer this question and how effective is health insurance and covering the costs of cancer treatments and what are the gaps in coverage that patients often experience? well, unfortunately, like i mentioned before, the insurance is don't cover the costs of the drug. the reason one is if a drug is shown to be applications in a certain type of cancer, it might be lagging and time for the approval regulation and insurance is loved to go on to the approval. if it's not, the approved insurance will not cover it regardless if it's a life saving drug, even though it's been proven. and there's been multiple randomized space phase 3 trials in terms of the drugs showing the applications. insurance is won't cover it . number 2, some are certain insurance companies won't cover it if the drug is not listed ncc

and guidelines, which is the name of our guidelines, our bible for treating certain types of cancer. so basically, the insurance won't cover or they won't cover fully unless it's on that, and that takes time itself to be listed on ncc and enter this as i'm talking in regards united states practice is another thing would be a cancer pathway. basically these pathways are formed by certain to a certain organizations of certain kinds organizations. and if there's a list in the pathway that insurance doesn't cover it, and then of course you have medicare with certain type of coverage, 80 percent, which a supplemental is needed to cover the rest. so sometimes it covers all, sometimes it covers non, it's very light bile in terms of you know, what kind of the cost uh, is a patient and car from the out of pocket as opposed with insurance covers. and to what extent are generic drugs and bio similar as contributing making cancer

treatment is more affordable. so they contribute. a significant portion of the bio similar is are basically just another synthetic version of the drug itself. and it's allow, allows for affordable fordable purchases from hospital or health care organizations in which they're able to purchase the drugs in an affordable manner. it's still quite expensive, but it has allowed for some hospitals and some private organizations to stay afloat because of the so synthetic variance and it bypasses the monopoly of certain drug companies. unfortunately, there's been a influx of bio similar uh, unfortunate or cert insurance companies which will purchase a certain type of bias on there. and then there's the hospital organization or the private organization, which only allows certain, formulated by similar. so there's head to head, you know, always battle and getting authorization and payment when dealing with different types of insurance and different types of health care organizations. um, yeah, it's, it's label but it, does it improve a cheaper affordable healthcare?

yes, absolutely. for certain types of patients and certain types of insurance is here in united states. either barriers or challenges in the adoption of generic alternatives. and how can these be addressed? basically, the barriers mostly is federal regulations at the approval for certain drugs. those are the biggest barriers because if they don't get their approval, if they don't have a certain regulation to go from a bench research to clinical face studies involving humans, then that that can lead to huge barriers going developing of a certain types of drugs, but also allow it to be affordable and covered by in certain insurances. so mostly it's government regulation and how it can be addressed is basically the uh, um, voting for the proper uh, regulations and the escalating the regulations on certain types of parts of the company and the regulating certain of to allow for

a better open market. and for less of on a monthly about creating cancer drugs and the pharmaceutical industry contributed to making cancer drugs more affordable without compromising innovation. yes, they can. um if the, you know, the certain rules on patents in terms of one particular drug company, i know of only allowing to access that certain type of drug allowing for a generic to be brought about more bio simulators that could, you know, lead to that. um, allowing less regulation in terms of research and making them more affordable for certain pharmaceutical companies instead of they're allowing to, you know, increase the price of certain drugs based off, you know, what they're, what they're doing. so those are the types of, you know, innovations that will allow to affordable access and health care, either existing models or practices that demonstrate a balance between profitability and accessibility. i literally touch on this basically clinical pathways and basically uh, health care teams are

a comprehensive uh, cancer organization. so basically, health care pack pathways are a pathway that was developed by the organization in terms of how to treat certain cancers. and which pathway allows you know, which way the physician or the clinician will allow to go to treat the patient. basically it's a standard of care for certain types of cancer patients. for example, if you have an early stage breast cancer, you want to go down this testing pathway. and if this test turns out to be positive, you go down that pathway and negative turn on the best. and it leads you to the proper treatment and ensure it is our start to recognize that more and starting to approve it based on those pathways and multiple different organizations of different pathways. but mostly generally the st. so the. ready pathways allow it to be is allow for less spending because they were approved and less for less error in terms of patient care. and the other thing i mentioned was the comprehensive cancer team. so basically, instead of the condition taken on the burden of being the social worker, the physical therapy is the dietician nutritionist that we have. nutritionist,

we have physical therapist, we have social workers, we have um, nurses, we have oral, we have certain pharmacist on the team and as a team, we cater to that one patient and we all focus on our respective specialties, and that has led to less hospitalizations, less emergency room visits in the, in the 1st year of kendrick treatment. so of our common thing is for patients who undergo chemo therapy, or immunotherapy, or any type of targeted therapy. 70 percent of them end up in the emergency room. and that's from a lack of education, or lack of access to certain specialties. and basically that could save up to $200000.00 a year for one patient. so those are the 22 mortality is that i see in my mind that have demonstrated a balance between profitability, accessibility for treatment. thank you so much, doctor has been for all your time today. the cancer continues to be an elusive disease as myriads of mutations exist. every cancer is caused by

a different set of mutations and as a tumor grows more and more mutations accumulate. this means that every tumor has an individual set of mutations. so a drive that works for one patient might have absolutely no effect on another. it is not a single disease, but rather a group of diseases with more than a 100 different types of cancers. they are also caused by different things, so no one strategy can prevent them. while we may never be able to completely cheer, cancer scientists are optimistic that vaccines, personalized medicines and smart lifestyle choices will help to prevent and treat a much greater proportion of cases than currently today. i'm christy. i thanks for watching and we'll see you right back here next time on the cost of everything. the

breaking news general valerie's illusion. the head of ukrainian armed forces throughout the conflict with russia is set from his post as follows. along the public risk between president zalinski and the outgoing commander in chief over failures on the battlefield. just for hours until the much anticipated tucker carlson interview with vladimir putin hits the journalist dreaming network at 11 pm gmc. you can watch the full broadcast here on archie. does decided to weaponized if you're not to say ideological really we will not by reading good, but it didn't stop all imports, desktop google pardon, but they will continue to import gas. there.